Windlas Biotech IPO Date, Price, GMP, Review, Allotment, Subscription, Analysis & Documents
- About Windlas Biotech
- Important Details – Windlas Biotech
- Objects of the Issue
- Windlas Biotech Limited Financials:
- Windlas Biotech IPO Price – Details
- Windlas Biotech IPO DRHP & RHP
- Windlas Biotech IPO Lot Size
- Windlas Biotech IPO Lead Managers
- Windlas Biotech Registrar
- Company Promoters
- Windlas Biotech IPO Allotment Date, Listing Date and other Important Dates
- Company Corporate Office
- Company Registered Office
- Windlas Biotech IPO – FAQS
About Windlas Biotech
Windlas Biotech is the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and lowsolubility, provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.
In Fiscal 2020, the market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry In addition to providing services and products in the CDMO market, the comany also sell the own branded products in the trade generics and OTC markets as well as export generic products to several countries.
The prevalence of chronic diseases in India has been increasing in the last few years, specifically in certain key therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies, that are treated with ‘multi-drug therapy’ by physicians, i.e. the specific use of two or more drugs for single or multiple chronic conditions in an individual. Moreover, multi-drug therapy has gained importance over the past few years in the healthcare sector and is expected to aid the growth of pharmaceutical consumption
The company have significant experience in developing and manufacturing generic fixed dose combinations. The focus has currently been on launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders
Important Details – Windlas Biotech
| Date | Details |
|---|---|
| February 19, 2001 | The company was incorporated as ‘Windlas Biotech Limited’ at New Delhi as a public limited company |
| March 5, 2001 | The company received the certificate for commencement of business from the RoC Delhi. |
| August 5, 2010 | The registered office of the company was shifted from the state of Delhi to the state of Uttarakhand |
| March 30, 2016 | The company was converted into a private limited company and name of the company changed to ‘Windlas Biotech Private Limited’ |
| April 3, 2021 | The company was converted from a private limited company to a public limited company and the name of the company was changed to ‘Windlas Biotech Limited’. |
Objects of the Issue
- Purchase of equipment required for (i) capacity expansion of our existing facility at Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant-II;
- Funding incremental working capital requirements of our Company;
- Repayment/prepayment of certain of our borrowings; and
- General corporate purposes
Windlas Biotech Limited Financials:
Summary of financial Information (Restated Consolidated Statement)
| Particulars | For the year ended (₹ in million) | ||
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
| Total Assets | 2,961.23 | 3,384.88 | 2,981.80 |
| Total income | 4,306.95 | 3,313.39 | 3,115.25 |
| Profit After Tax | 155.70 | 162.13 | 638.22 |
Windlas Biotech IPO Price – Details
| Description | WINDLAS IPO Details |
|---|---|
| Public Issue | Initial Public offer of [.] Equity Shares of ₹5 (aggregating up to ₹401.54 Cr) comprising a Fresh Issue [.] Eq Shares of ₹5 (aggregating up to ₹165.00 Cr) and an Offer for sale of up to 5,142,067 equity shares |
| Issue Open Date | 04-Aug-21 |
| Issue Close Date | 06-Aug-21 |
| Issue Type | Book Building |
| IPO Price Band | ₹ 448 – ₹ 460 |
| Face Value | ₹ 5 |
| Market Lot | 30 Equity Shares and in multiples thereof |
| Minimum Order Quantity | 30 Equity Shares |
| Maximum Subscription Amount for Retail Investor | Rs. 2,00,000 |
| Listing | NSE, BSE |
| NSE Symbol | WINDLAS |
| IPO Market Timings | 10.00 a.m. to 5.00 p.m. |
Windlas Biotech IPO DRHP & RHP
Windlas Biotech IPO Lot Size
| Application | Lots | No of Shares | Amount (Rs) |
| Minimum | 1 | 30 | ₹ 13,800 |
| Maximum | 14 | 420 | ₹ 1,93,200 |
Windlas Biotech IPO Lead Managers
- SBI Capital Markets Limited
- DAM Capital Advisors Limited
- IIFL Securities Limited
Windlas Biotech Registrar
Company Promoters
- Ashok Kumar Windlass,
- Hitesh Windlass,
- Manoj Kumar Windlass
- Akw Wbl Family Private Trust
Windlas Biotech IPO Allotment Date, Listing Date and other Important Dates
| Details | Date |
|---|---|
| Bid / Offer Opens on | 04-Aug-21 |
| Bid / Offer Closes on | 06-Aug-21 |
| Finalisation of Basis of Allotment | 11-Aug-21 |
| Initiation of refunds | 12-Aug-21 |
| Credit of the Equity Shares | 13-Aug-21 |
| Commencement of trading – Listing | 17-Aug-21 |
Company Corporate Office
705-706, Vatika Professional Point,
Sector-66, Golf Course Extension Road,
Gurgaon 122 001,
Haryana, India;
Tel: +91 124 2821030
Company Registered Office
40/1, Mohabewala Industrial Area,
Dehradun 248 110,
Uttarakhand, India;
Tel: +91 135 6608000
Corporate Office:
Windlas Biotech IPO – FAQS
When Windlas Biotech IPO will open ?
The Windlas Biotech IPO opens on Aug 04, 2021 and closes on Aug 08, 2021
What is the lot size of Windlas Biotech IPO ?
The Windlas Biotech IPO lot size is 30 Shares and the minimum order quantity is 30 Shares.
What is the price band for Windlas Biotech IPO ?
The Windlas Biotech IPO price band at Rs.448 to Rs.460 per share
Who is the Registrar for Windlas Biotech IPO ?
The Registrar is Link Intime India Private Limited
How to apply in Windlas Biotech IPO through UPI?
Check the step by step process here – Click here
Follow us on Telegram for all latest updates
